HomeBUSINESS
BUSINESS

I/O in Lung Cancer - 1: US Merck Sweeping Frontline NSCLC Space with Keytruda
(Aug.10.2018)

Hiromichi Shirasawa, Japan Development Head, MSD
By Takashi Ebisawa

Four years after Opdivo (nivolumab) won the world’s first approval in Japan, immune checkpoint inhibitors are reshaping the landscape of lung cancer treatments, with differences in strategies pursued by five camps of developers - Ono Pharmaceutical/Bristol-Myers Squibb, US Merck, AstraZeneca, Roche, and Merck KGaA/Pfizer - becoming more and more evident. This series aim to sort out their statuses and approaches in the red-hot development race as well as market and clinical use outlooks for I/O therapies ...
(LOG IN FOR FULL STORY)